4D Molecular Therapeutics, Inc.
FDMTNasdaqCIK 1650648HealthcareFiscal year ends Dec 31
Reports and events: 100 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2023-11-2221:20 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-23-282259 |
| 2023-11-0921:23 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-062109 |
| 2023-11-0921:20 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-062103 |
| 2023-09-1301:17 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-23-233693 |
| 2023-08-0920:30 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-040661 |
| 2023-08-0920:26 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-040653 |
| 2023-07-1101:31 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-23-184867 |
| 2023-05-2520:58 ET | 8-K | 5.07 Shareholder vote results | 0001193125-23-154338 |
| 2023-05-1122:13 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-020703 |
| 2023-05-1122:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-020699 |
| 2023-05-0920:43 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-139482 |
| 2023-04-1212:30 ET | DEF 14A | Proxy statementPeriod 2023-05-23 | 0001193125-23-098511 |
| 2023-03-1520:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-008146 |
| 2023-03-1520:13 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000950170-23-008142 |
| 2023-02-0300:08 ET | 8-K | 8.01 Other events | 0001193125-23-023004 |
| 2023-01-2621:50 ET | 8-K | 8.01 Other events | 0001193125-23-016298 |
| 2022-11-0921:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-023839 |
| 2022-11-0821:02 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0000950170-22-023185 |
| 2022-09-2720:25 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-22-252180 |
| 2022-08-1120:19 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-016890 |
| 2022-08-1120:15 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0000950170-22-016882 |
| 2022-06-2123:52 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-22-176718 |
| 2022-05-2721:24 ET | 8-K | 5.07 Shareholder vote results | 0001193125-22-162490 |
| 2022-05-1220:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-009715 |
| 2022-05-1220:29 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0000950170-22-009702 |
| 2022-04-1320:05 ET | DEF 14A | Proxy statementPeriod 2022-05-23 | 0001193125-22-104263 |
| 2022-03-2820:44 ET | 10-K | Annual reportPeriod 2021-12-31 | 0000950170-22-004794 |
| 2022-03-2820:38 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-004792 |
| 2022-02-2221:45 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-22-048643 |
| 2022-01-1112:01 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-22-006255 |
| 2021-11-1021:20 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-21-004099 |
| 2021-11-1021:16 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0000950170-21-004086 |
| 2021-10-2621:09 ET | S-1 | Registration statement | 0001193125-21-308105 |
| 2021-10-2610:30 ET | 8-K | 8.01 Other events | 0001193125-21-307156 |
| 2021-10-1320:37 ET | 8-K | 8.01 Other events | 0001193125-21-297865 |
| 2021-09-2420:59 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-21-282451 |
| 2021-08-1220:21 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0001564590-21-043998 |
| 2021-08-1220:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-043986 |
| 2021-06-2520:01 ET | 8-K | 1.02 Termination of a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001564590-21-034575 |
| 2021-05-2020:06 ET | 8-K | 5.07 Shareholder vote results | 0001564590-21-029069 |
| 2021-05-1320:21 ET | 10-Q | Quarterly reportPeriod 2021-03-31 | 0001564590-21-027576 |
| 2021-05-1320:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-027559 |
| 2021-04-0621:22 ET | DEF 14A | Proxy statementPeriod 2021-05-17 | 0001193125-21-107762 |
| 2021-03-2520:19 ET | 10-K | Annual reportPeriod 2020-12-31 | 0001564590-21-015502 |
| 2021-03-2520:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-21-094446 |
| 2020-12-1522:01 ET | 8-K | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-20-318186 |
| 2020-12-1011:05 ET | S-1/A | Registration statement, amended | 0001193125-20-314317 |
| 2020-12-0711:15 ET | S-1/A | Registration statement, amended | 0001193125-20-311111 |
| 2020-11-1722:25 ET | S-1 | Registration statement | 0001193125-20-296146 |
| 2019-09-3021:12 ET | S-1 | Registration statement | 0001193125-19-258924 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.